REED JOHN C

EVP Reed sells 53,931 shares at $243.00 for $13.1M, reducing JNJ stake by 83.5%

John C. Reed, EVP of Innovative Medicine, R&D, executed 3 separate sales totaling 53,931 shares for $13,105,233.00 on 2026-02-17, leaving him with 10,658 shares post-transaction—a net reduction of 83.5% versus pre-transaction holdings of 64,589 shares. The transactions occurred at $243.00 per share, near the 52-week high of $244.99, with JNJ stock up 12.0% over the prior 30 days and 20.6% over 90 days. Across his same-ticker history at JNJ, Reed's 2 prior sells (October 2025 and July 2025) both generated positive subsequent returns (13.9% and 16.9% at the 90-day mark), indicating neither was well-timed as an exit before a decline. No FLAGS were provided, and this represents discretionary open-market activity rather than a planned trading program. The near-complete liquidation of a long-held position by a senior R&D executive warrants examination of whether capital reallocation or portfolio considerations drove the decision.

EVP Reed sells 21,721 shares of JNJ for $4.2M at $192.71; position reduced 67.1% to 10,658 shares held.

John C. Reed, EVP of Innovative Medicine, R&D, sold 21,721 shares on 2025-10-17 at $192.71 per share, reducing his holdings from 32,379 shares to 10,658 shares—a 67.1% reduction in position size for $4,185,793.09 in proceeds. The sale occurred near the 52-week high of $193.72, with the stock up 10.0% over 30 days and 15.4% over 90 days. His prior sell at JNJ on 2025-07-17 resulted in 90-day returns of +16.9%, indicating the stock rose after that sale; this cross-ticker pattern of positive post-sale returns (avg 90d return +16.9%, 0.00% well-timed rate) is typical of poorly-timed sell decisions in his history. The substantial reduction in his R&D leadership stake warrants attention given the strategic importance of innovation to JNJ's competitive positioning.

EVP Reed sells 19,137 JNJ shares for $3.1M, reducing stake 64.2% to 10,658 shares

John C. Reed, EVP of Innovative Medicine R&D, executed a substantial sale of 19,137 shares at $163.55 on 2025-07-17, generating $3,129,829.56 in proceeds and reducing his holdings by 64.2% from 29,795 to 10,658 shares. The transaction occurred near the upper end of the 52-week trading range ($142.06–$167.70), with stock up 8.6% over 30 days and 4.0% over 90 days. Johnson & Johnson's current valuation (P/E 18.07, $21.9B quarterly revenue, $11.0B net income, +4.3% annual growth) reflects a mature, profitable healthcare conglomerate, and Reed's partial liquidation of a substantial position warrants investor attention to potential changes in his conviction regarding the company or broader portfolio reallocation needs.